An optimized, clinically relevant mouse model of cisplatin-induced ototoxicity

Area of Science:

• Ototoxicity research
• Cancer therapy side effects
• Animal modeling

Background:

• Cisplatin chemotherapy is a vital cancer treatment but frequently causes permanent hearing loss (ototoxicity) in survivors.
• Current animal models inadequately replicate clinical cisplatin administration, leading to high mortality and limited insights into hearing loss mechanisms.
• Existing models fail to assess long-term hearing changes or test protective therapies effectively.

Purpose of the Study:

• To develop an optimized mouse model for studying cisplatin-induced ototoxicity.
• To create a model that better reflects clinical cisplatin administration protocols.
• To facilitate research into the mechanisms of hearing loss and the development of protective therapies.

Main Methods:

• Implemented a multi-cycle cisplatin administration protocol in mice.
• The protocol was designed to mimic clinical dosing schedules and levels.
• Evaluated hearing sensitivity changes and mortality rates.

Main Results:

• The optimized multi-cycle protocol induced significant hearing loss in mice.
• This protocol demonstrated a substantially lower mortality rate compared to previous models.
• The model effectively replicates the type and degree of hearing loss seen in human patients.

Conclusions:

• The developed mouse model accurately represents cisplatin-induced ototoxicity with reduced mortality.
• This optimized model serves as a valuable platform for investigating ototoxicity mechanisms.
• It will aid in developing and testing therapies to preserve hearing in cancer patients undergoing cisplatin treatment.